Search

Memorial Sloan Kettering shares results of a recent review by our Boards of Overseers and Managers, as well as additional policies we are considering to enhance communication, transparency, disclosure, and oversight of outside activities and industry-supported clinical trials.

… Saturday, September 29, 2018 Today, Memorial Sloan Kettering shared results of a recent review by our Boards of Overseers and Managers, as well as additional policies we are considering to enhance communication, transparency, disclosure, and oversight of outside activities and industry-supported clinical

Read how a clinical trial is changing the outlook for some people with lung cancer.

… Monday, May 24, 2021 Update: On May 28, 2021, the US Food and Drug Administration granted accelerated approval to sotorasib (Lumakras TM ) for the treatment of advanced non-small cell lung cancer driven by the KRAS -G12C mutation in patients who have already received at least one other treatment. The

New MSK research helps win the approval of a drug to treat one type of metastatic non-small cell lung cancer; shows the effectiveness of cryoablation for large breast cancer tumors; identifies a gene essential for the formation of a common childhood brain tumor; and unlocks the secrets of natural killer cell metabolism.

… Thursday, March 28, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK)  helps win the approval of a drug to treat one type of metastatic non-small cell lung cancer; shows the effectiveness of cryoablation for large breast cancer tumors; identifies a gene essential for the formation of

Every day, your commitment to funding life-changing cancer research at Memorial Sloan Kettering is ensuring a brighter future for people with cancer around the world. Thank you for your continued support.

… Thursday, July 1, 2021 Woman with a pom pom at the Cycle for Survival event at MetLife Stadium Cycle for Survival participants gathered at MetLife Stadium in New Jersey on May 1 and 2, 2021, for a socially distanced outdoor ride. Woman with two pom poms on stage at the Cycle for Survival event at MetLife

MSK experts say the Shield blood test is not the best way to detect colorectal cancer and instead recommend colonoscopy or a stool test for those who can’t have a colonoscopy.

… Wednesday, August 13, 2025 Only about two-thirds of the people who should have a  colonoscopy  actually get one. In the quest to improve colorectal cancer screening rates, companies are developing tests that are less invasive. The first blood test to detect  colon cancer and  rectal cancer , called Shield

Los expertos de MSK afirman que el análisis de sangre Shield no es la mejor forma de detectar el cáncer colorrectal y, en su lugar, recomiendan la colonoscopia o un análisis de heces para aquellas personas que no pueden someterse a una colonoscopia.

… Wednesday, August 13, 2025 Solo alrededor de dos tercios de las personas que deberían realizarse una  colonoscopia  realmente lo hacen. En la búsqueda por mejorar las tasas de detección del cáncer colorrectal, las empresas están desarrollando pruebas menos invasivas. El primer análisis de sangre que

In her role at MSK, Mack will direct the evolution and improvement of all business processes.

… Monday, March 27, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that LaKisha Mack, MSHA , has joined the institution as the inaugural Chief Administrative Officer (CAO). A seasoned healthcare business leader with more than two decades of experience in institutional finance, operations

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.

… Wednesday, June 2, 2021 New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD , and colleagues found that patients who received nivolumab (Opdivo®)  after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research

The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program will facilitate tailored mentorship with MSK faculty, while providing access to MSK’s drug development expertise, resources, and a pathway for future collaboration in the MSK Therapeutics Accelerator.

… Friday, February 6, 2026 The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program

During the height of the COVID-19 pandemic, when the constant sound of sirens filled the streets of New York City, Memorial Sloan Kettering Deputy Chief Nurse Kevin Browne found himself in a somewhat unfamiliar place: in the back of an ambulance headed to MSK—this time as a patient. 

… Friday, October 9, 2020 During the height of the COVID-19 pandemic, when the constant sound of sirens filled the streets of New York City and the surrounding communities, Memorial Sloan Kettering Deputy Chief Nurse Kevin Browne found himself in a somewhat unfamiliar place: in the back of an ambulance